Applic		•	Applicant(s)	
Notice of Allowability	09/697,613		CHAPMAN ET AL.	
	Examiner		Art Unit	
	Dr. Kailash C. S	rivastava	1651	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.				
 This communication is responsive to <u>amendment filed 11/04/2003</u>. The allowed claim(s) is/are <u>1 and 9 to 12</u>. 				
3. The drawings filed on <u>26 October 2000</u> are accepted by the Examiner.				
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
 Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). 				
* Certified copies not received:				
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.				
(a) The translation of the foreign language provisional application has been received.				
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.				
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE				
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.				
8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.				
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No				
(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner.				
(c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No				
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).				
9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR 1	osit of BIOLOGIC THE DEPOSIT OF	CAL MATERIAL r BIOLOGICAL MA	must be submitted TERIAL.	. Note the
Attachment(s)				
1 Notice of References Cited (PTO-892)	5∐ N	otice of Informal Pa	atent Application (PT	O-152)
2☐ Notice of Draftperson's Patent Drawing Review (PTO-948)		terview Summary ((PTO-413), Paper No	o. <u>0122</u> .
3☐ Information Disclosure Statements (PTO-1449 or PTO/SB/	8), 7⊠ Ex	xaminer's Amendm	ent/Comment	
Paper No 4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ E: 9∐ O		nt of Reasons for All	owance
				:

Examiner's Amendment

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Cynthia A. Kozakiewicz on 01/22/2004.

In the Claims:

- Claims 1, 11 and 23 are cancelled.
- Claims 24 and 25 have been added as follows:
 - 24. A method of treating atherosclerosis in a subject, comprising identifying a subject suffering from atherosclerosis and administering to said subject a composition comprising cystatin C in an effective amount to reduce a symptom of atherosclerosis.
 - 25. A method of reducing the risk of developing atherosclerosis in a subject, comprising identifying a subject at risk of developing atherosclerosis and administering to said subject a composition comprising cystatin C in an effective amount to reduce the risk of developing atherosclerosis.
- In Claim 9, "1" has been replaced with --24--.
- In Claim 10, "1" has been replaced with --24--.
- In Claim 12, "11" has been replaced with --25--.
- 2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Kailash C. Srivastava whose telephone number is (571) 272-0923. The examiner can normally be reached on Monday to Thursday from 7:30 A.M. to 6:00 P.M. (Eastern Standard or Daylight Savings Time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (571) 272-0926 Monday through Thursday.

The fax phone number for the organization where this application or proceeding is assigned is (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Kailash C. Srivastava, Ph.D.

Patent Examiner Art Unit <u>1651</u> (571) 272-0923 January 29, 2004

CHRISTOPHER R.TATE PRIMARY EXAMINER